Trial Profile
A Randomized Double-blinded Trial Comparing DEsmopressin to FEsoterodine in the Treatment of Severe Nocturia in Women Aged 65 and olDer: The DEFEND Trial
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 30 Jul 2018
Price :
$35
*
At a glance
- Drugs Fesoterodine (Primary) ; Desmopressin
- Indications Nocturia
- Focus Therapeutic Use
- Acronyms DEFEND trial
- 11 Nov 2016 Status changed from not yet recruiting to discontinued.
- 20 Oct 2014 New trial record